- Home
- Products
- Customized ADCs
- CD19
- Anti-CD19 (Blinatumomab)-MC-MMAF ADC
Anti-CD19 (Blinatumomab)-MC-MMAF ADC (CAT#: ADC-W-778)
This ADC product is comprised of an anti-CD19 monoclonal antibody conjugated via a MC linker to MMAF. The MMAF is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, MMAF binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.
- ADC Target
- ADC Antibody
- ADC Linker
- ADC payload drug
- Name
- CD19
- Alternative Names
- CD19; CD19 molecule; CD19 antigen; B-lymphocyte antigen CD19; differentiation antigen CD19; T-cell surface antigen Leu-12; B-lymphocyte surface antigen B4; B4; CVID3; MGC12802;
- Target Entrez Gene ID
- 930
- Target UniProt ID
- P15391
- Overview
- Lymphocytes proliferate and differentiate in response to various concentrations of different antigens. The ability of the B cell to respond in a specific, yet sensitive manner to the various antigens is achieved with the use of low-affinity antigen receptors. This gene encodes a cell surface molecule which assembles with the antigen receptor of B lymphocytes in order to decrease the threshold for antigen receptor-dependent stimulation.
- Overview
- Anti-CD19 (scFv-kappa-heavy)-(scFv-heavy-kappa) antibody, Blinatumomab
- Generic name
- Blinatumomab
- Host animal
- Mouse
- Species Reactivity
- Human
- Name
- MC (maleimidocaproyl)
- Description
- Noncleavable linkers, is considered noncleavable-meaning linker cleavage, and payload release does not depend on the differential properties between the plasma and some cytoplasmic compartments. Instead, the release of the cytotoxic drug is postulated to occur after internalization of the ADC via antigen-mediated endocytosis and delivery to lysosomal compartment, where the antibody is degraded to the level of amino acids through intracellular proteolytic degradation.
- Name
- MMAF
- Description
- Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-ITGA4+ITGB7 (Abrilumab)-MC-MMAF ADC (CAT#: ADC-W-2386)
- Anti-HGF (Flanvotumab)-SMCC-DM1 ADC (CAT#: ADC-W-1190)
- Anti-S. epidermidis LTA (Pagibaximab)-SPDB-DM4 ADC (CAT#: ADC-W-2259)
- Anti-CA9-MCC-MMAE ADC (CAT#: ADC-W-318)
- Anti-SLAMF6 (clone 11A1)-Mc-MMAF ADC (CAT#: ADC-W-307)
- Anti-CD74 (011 (B))-Mc-MMAF ADC (CAT#: ADC-W-039)
- Anti-EGFR (Imgatuzumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-1069)
- Anti-CTLA4 (Ipilimumab)-MC-MMAF ADC (CAT#: ADC-W-1000)
- Anti-SELP (Inclacumab)-SPDB-DM4 ADC (CAT#: ADC-W-1755)
- Anti-TNFRSF8 (Iratumumab)-SPDB-DM4 ADC (CAT#: ADC-W-1887)
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for ADC-W-778. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
Same Linker
Same Payload
| CAT# | Product Name | Linker | Payload |
| ADC-W-779 | Anti-CD19 (Blinatumomab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
| ADC-W-2517 | Anti-CD19 (Denintuzumab)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
| ADC-W-2516 | Anti-CD19 (Denintuzumab)-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
| ADC-W-781 | Anti-CD19 (Blinatumomab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
| ADC-W-2518 | Anti-CD19 (Denintuzumab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
| CAT# | Product Name | Linker | Payload |
| ADC-W-485 | Anti-EphA2 (clone 1C1)-Mc-MMAF ADC | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
| ADC-W-2622 | Anti-NCAM1 (Lorvotuzumab )-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-452 | Anti-CD70 (clone 1F6)-Mc-MMAF ADC | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
| ADC-W-2612 | Anti-MS4A1 (Rituximab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-537 | Anti-TPBG-Mc-MMAF ADC | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
| CAT# | Product Name | Linker | Payload |
| ADC-W-2591 | Anti-EGFR (Cetuximab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-AA-063 | Anti-HIgG(Fab)-N-MMAF ADC | Noncleavable linkers | MMAF |
| ADC-W-2600 | Anti-GPNMB (Glembatumumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-2579 | Anti-CEACAM5-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-2561 | Anti-MSLN (Anetumab )-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
